MALT Lymphoma Clinical Trial
Official title:
Phase II Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to
induce objective/histologic responses in patients with MALT lymphoma.
The secondary objectives are to evaluate the safety of Lenalidomide in this patient
population and to evaluate the impact of Lenalidomide on progression free survival.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05003141 -
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
|
Phase 1 | |
| Completed |
NCT01015248 -
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma
|
Phase 2 | |
| Completed |
NCT00373646 -
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
|
Phase 2 | |
| Completed |
NCT00201422 -
Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma
|
N/A | |
| Completed |
NCT00783367 -
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
|
Phase 2 | |
| Active, not recruiting |
NCT01808599 -
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
|
Phase 2 | |
| Completed |
NCT00117156 -
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05544019 -
Study of SGR-1505 in Mature B-Cell Neoplasms
|
Phase 1 | |
| Completed |
NCT00373906 -
Velcade in MALT Lymphoma Patients
|
Phase 2 |